On July 30, 1999, the Company sold its drug discovery assets and ceased its internal
drug discovery operations and research efforts for collaborative partners.
«We have already started up parts of the
operation, and are now looking to recruit scientists with
drug discovery and development expertise to our eight facilities», says Per Arvidsson, Platform Director for the Stockholm site of the DDD platform.